摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[(7-chloro-2,4(1H,3H)-quinazolinedione-3-yl)sulfonyl]anthranilic acid | 259536-74-8

中文名称
——
中文别名
——
英文名称
4-[(7-chloro-2,4(1H,3H)-quinazolinedione-3-yl)sulfonyl]anthranilic acid
英文别名
4-[(7-chloro-2,4 (1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic Acid;4-[(7-Chloro-2,4(1H,3H)-Quinazolinedion-3-yl)Sulfonvl]Anthranilic Acid;2-amino-4-[(7-chloro-2,4-dioxo-1H-quinazolin-3-yl)sulfonyl]benzoic acid
4-[(7-chloro-2,4(1H,3H)-quinazolinedione-3-yl)sulfonyl]anthranilic acid化学式
CAS
259536-74-8
化学式
C15H10ClN3O6S
mdl
——
分子量
395.78
InChiKey
MVSVIOVDISKPIS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    26
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    155
  • 氢给体数:
    3
  • 氢受体数:
    7

反应信息

点击查看最新优质反应信息

文献信息

  • PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT
    申请人:——
    公开号:US20020183338A1
    公开(公告)日:2002-12-05
    A medicament for the prevention or treatment containing a chymase inhibitor, as an effective component, which is a side effect-free, safe medicament for prevention or treatment of fibrosis of the skin or various viscera which suppresses the progression of the condition, prevents the progression of complications, and improves the quality of life of the patient, wherein a quinazoline derivative having the formula (I): 1 or a pharmaceutically acceptable salt thereof is included therein.
    一种预防或治疗皮肤或各种内脏纤维化的药物,含有一种作为有效成分的针对钠胃蛋白酶抑制剂,是一种无副作用、安全的药物,可抑制病情的进展,预防并改善并发症的发展,并提高患者的生活质量,其中包括具有以下结构式(I)的喹唑啉衍生物或其药用盐。
  • Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient
    申请人:——
    公开号:US20020183339A1
    公开(公告)日:2002-12-05
    A medicament safe and free from side effects, for the prevention or treatment of dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen, which suppresses the progress of the condition and improves the quality of life of the patient, which medicament treats dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen by including a quiazoline derivative having the formula (I) or (II) or its pharmaceutically acceptable salt as an effective ingredient: 1
    一种安全且无副作用的药物,用于预防或治疗表现为双相炎症反应的皮炎或由重复暴露于抗原引起的皮炎,该药物抑制病情进展并改善患者的生活质量,其中包括一种喹唑啉衍生物,其具有公式(I)或(II)或其药学上可接受的盐作为有效成分,用于治疗表现为双相炎症反应的皮炎或由重复暴露于抗原引起的皮炎。
  • Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
    申请人:Suntory Limited
    公开号:US06500835B2
    公开(公告)日:2002-12-31
    A medicament for the prevention or treatment containing a chymase inhibitor, as an effective component, which is a side effect-free, safe medicament for prevention or treatment of fibrosis of the skin or various viscera which suppresses the progression of the condition, prevents the progression of complications, and improves the quality of life of the patient, wherein a quinazoline derivative having the formula (I): or a pharmaceutically acceptable salt thereof is included therein.
    一种药物,用于预防或治疗纤维化,其有效成分为一种无副作用、安全的基质酶抑制剂,可抑制病情进展,预防并发症的进展,提高患者的生活质量。其中包括具有以下结构式(I)的喹唑啉衍生物或其药学上可接受的盐。
  • Method of treating dermatitis comprising administering a chymase inhibitor
    申请人:Asubio Pharma Co., Ltd.
    公开号:US07618977B2
    公开(公告)日:2009-11-17
    Medicaments for the treatment of dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen, having quinazolidone derivatives of formula I or II that are herein defined, are disclosed.
    本文揭示了用公式I或II所定义的喹唑酮衍生物治疗表现为双相炎症反应或由重复暴露于抗原引起的皮炎的药物。
  • INHIBITORS AGAINST VASCULAR LIPID DEPOSITION CONTAINING CHYMASE-INHIBITING SUBSTANCES
    申请人:SUNTORY LIMITED
    公开号:EP1142586A1
    公开(公告)日:2001-10-10
    There is provided a preventive or therapeutic agent for diseases accompanied by abnormal vascular function in which lipid deposition in the blood vessel is involved, said agent comprising a chymase inhibitor as an active ingredient. As the chymase inhibitor, a quinazoline derivative represented by the following formula is used. In the above formula, the ring A represents an aromatic ring.
    本发明提供了一种预防或治疗剂,用于治疗伴有血管功能异常的疾病,其中涉及血管中的脂质沉积,所述制剂包括作为活性成分的糜蛋白酶抑制剂。 作为糜蛋白酶抑制剂,使用了由下式表示的喹唑啉衍生物。 在上式中,环 A 代表芳香环。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐